BPC-157 vs TB-500 in Preclinical Research
BPC-157 and TB-500 are two of the most frequently studied peptides in preclinical tissue research. They differ in origin, structure and the pathways researchers investigate.
Origin and structure
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids, whose sequence is derived from a protein fragment found in gastric juice. It is notable in the literature for its stability in solution compared with many short peptides.
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a 43-amino-acid protein that binds actin. Research material sold as TB-500 is typically a short fragment or the full sequence, so check the product specification and COA.
Pathways studied
Preclinical studies of BPC-157 have examined angiogenesis signaling, nitric oxide pathways, and growth factor receptor expression in animal and cell models.
Studies of Thymosin Beta-4 and its fragments focus on actin sequestration, cell migration, and cytoskeletal dynamics in cell culture and animal models.
Why they are compared
Both peptides appear in the tissue-repair literature, so they are often discussed together. Their mechanisms are distinct, which is why some research groups study them side by side or in combination in experimental protocols.
Findings from animal and in-vitro models do not establish safety or effects in humans. Neither compound is approved for human use.
Choosing material for a study
Confirm identity and purity on the batch certificate, record the lot number in your lab notebook, and follow your institution's handling procedures. Niho Labs supplies both peptides, and a blend, for laboratory research use only.